RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

RBC Capital analyst Leonid Timashev maintained a Buy rating on Insmed yesterday and set a price target of $200.00. The company’s shares closed yesterday at $161.00.

President's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Timashev covers the Healthcare sector, focusing on stocks such as Exelixis, Cytokinetics, and Insmed. According to TipRanks, Timashev has an average return of 19.0% and a 56.44% success rate on recommended stocks.

In addition to RBC Capital, Insmed also received a Buy from Wells Fargo’s Tiago Fauth in a report issued today. However, on the same day, TipRanks – Google downgraded Insmed (NASDAQ: INSM) to a Hold.

Based on Insmed’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $142.34 million and a GAAP net loss of $370.02 million. In comparison, last year the company earned a revenue of $93.43 million and had a GAAP net loss of $220.52 million

Based on the recent corporate insider activity of 133 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INSM in relation to earlier this year. Earlier this month, William Lewis, the Chair and CEO of INSM sold 3,009.00 shares for a total of $470,427.06.